Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sonnet BioTherapeutics Holdings, Inc. - Common Stock (NQ:SONN)

4.470 -0.260 (-5.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sonnet BioTherapeutics Holdings, Inc. - Common Stock

< Previous 1 2 3 Next >
Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410)
- SON-1410 (IL18-FHAB-IL12), a bispecific combination of Interleukins 18 and 12, was selected based on data generated in a mouse melanoma study comparing three bispecific constructs - Selection of the... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering
PRINCETON, NJ / ACCESSWIRE / August 19, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Topics Regulatory Compliance
Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update
Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update - Expanded F H AB Intellectual Property Portfolio - Completed $15.9 million At-The-Market Financing -... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Topics Intellectual Property
Sonnet BioTherapeutics Announces Change in Date of Annual Meeting
- Annual Meeting to be Held Thursday July 15, 2021. PRINCETON, NJ / ACCESSWIRE / June 14, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology
U.S. Patent and Trademark Office issued US Patent No. 11,028,166 for the Company's Fully Human Albumin Binding Domain Fusion Proteins PRINCETON, NJ / ACCESSWIRE / June 8, 2021 / Sonnet BioTherapeutics... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Topics Intellectual Property
Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update
- SON-1010, fully-human IL-12 configured using FHAB platform, advancing towards IND submission - At-The-Market offering program resulted in net proceeds of $10.2 million PRINCETON, NJ / ACCESSWIRE /... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP)
- The No Observed Adverse Event Level (NOAEL) following repeated administration was more than 50 times the anticipated equivalent human clinical dose in NHP with no evidence of cytokine release... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics
- New Life Therapeutics (NLT) to develop low-dose Interleukin 6 for Diabetic Peripheral Neuropathy in ASEAN territories - Upfront and potential milestone payments totaling up to $21 Million with up to... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.